Full Press Release Details
IDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE574, a Potential First In Class Dual Inhibitor of KAT6 7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer.
IDYA
IDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE574, a Potential First In Class Dual Inhibitor of KAT6 7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
Key Takeaway: IDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE574, a Potential First In Class Dual Inhibitor of KAT6 7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer